Replies to post #11548 on Titan Pharmaceuticals Inc (TTNP)

[shadolane]

Thanks for your comments and insight.

After so many years at this and going through bouts of optimism with Titan's various drugs it's easy top lose the optimism.

It seems like whatever is being attempted Titan has a funny way of not executing. In this case it's not all on their plate. But what is on their plate is slow in developing. With them being or maybe becoming cash deficient I am always concerned about dilution on top of a general decline in pps.

Hopefully we see some acceleration in implant business.

I was into another company with a cancer drug that was a first of a kind and its launch was and still is anemic. You may know them, CRIS and Erivedge.

I hope we all don't experience an experience like that.

Guess we will see.

GLTA

And thanks again for your inputs.

[Serenity3]

really appreciate all your analytical posts, very much; re: implants... news for upcoming submission on implant for naltrexone for opiate addiction ....AND NKTR popped 40% as it will submit NDA for chronic pain ... NKTR-181 reportedly "addiction resistant" and has FDA fast track.. both news stories popped in the last few days & probably contributed to TTNP dump... point is there is a lot of competition out there and this management team can't just mosey along as they have been allowed to do so by the Board ... in shareholder's best interest if company is sold... they have too many shares outstanding and very little cash relative to that share count... did Sunil say a burn rate of 6 mil/yr... they don't have much time to be conducting pre-clinical trials w/slow ramp up in probuphine while balooning share count by printing more shares for stock options ...probuphine and it's promise needs to be transferred to stronger hands... possibly Idivior's